133 related articles for article (PubMed ID: 38412650)
1. New 2-oxoindole derivatives as multiple PDGFRα/ß and VEGFR-2 tyrosine kinase inhibitors.
Ezelarab HAA; Abd El-Hafeez AA; Ali TFS; Sayed AM; Hassan HA; Beshr EAM; Abbas SH
Bioorg Chem; 2024 Apr; 145():107234. PubMed ID: 38412650
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel pyrazole based Urea/Thiourea derivatives as multiple targeting VEGFR-2, EGFR
Fadaly WAA; Nemr MTM; Kahk NM
Bioorg Chem; 2024 Jun; 147():107403. PubMed ID: 38691909
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel thiophene-3-carboxamide derivatives as potential VEGFR-2 inhibitors with anti-angiogenic properties.
Li T; Wang J; Feng L; Zhou Q; Xie Q; Shen Y; Ji R; Liu X; Wang Y; Hu C
Bioorg Chem; 2024 Jun; 147():107358. PubMed ID: 38626490
[TBL] [Abstract][Full Text] [Related]
4. Exploring new quinazolin-4(3H)-one derivatives as CDK2 inhibitors: Design, synthesis, and anticancer evaluation.
Ibrahim BT; Allam HA; El-Dydamony NM; Fouad MA; Mohammed ER
Drug Dev Res; 2024 Apr; 85(2):e22163. PubMed ID: 38419305
[TBL] [Abstract][Full Text] [Related]
5. New antiproliferative 3-substituted oxindoles inhibiting EGFR/VEGFR-2 and tubulin polymerization.
Ezelarab HAA; Ali TFS; Abbas SH; Sayed AM; Beshr EAM; Hassan HA
Mol Divers; 2024 Apr; 28(2):563-580. PubMed ID: 36790582
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, docking study, and antitumor evaluation of benzamides and oxadiazole derivatives of 3-phenoxybenzoic acid as VEGFR-2 inhibitors.
Heriz MH; Mahmood AAR; Yasin SR; Saleh KM; AlSakhen MF; Kanaan SI; Himsawi N; Saleh AM; Tahtamouni LH
Drug Dev Res; 2024 May; 85(3):e22186. PubMed ID: 38643351
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of novel hexahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives as potential anticancer agents with antiangiogenic activity via VEGFR-2 inhibition, and down-regulation of PI3K/AKT/mTOR signaling pathway.
Seif SE; Mahmoud Z; Wardakhan WW; Abdou AM; Hassan RA
Drug Dev Res; 2023 Aug; 84(5):839-860. PubMed ID: 37016480
[TBL] [Abstract][Full Text] [Related]
9. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
[TBL] [Abstract][Full Text] [Related]
10. Benzimidazole-oxindole hybrids as multi-kinase inhibitors targeting melanoma.
Allam RM; El Kerdawy AM; Gouda AE; Ahmed KA; Abdel-Mohsen HT
Bioorg Chem; 2024 May; 146():107243. PubMed ID: 38457953
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, Docking Studies and Molecular Dynamics Simulation of New 1,3,5-Triazine Derivatives as Anticancer Agents Selectively Targeting Pancreatic Adenocarcinoma (Capan-1).
Asghar S; Hameed S; Al-Masoudi NA; Saeed B; Shtaiwi A
Chem Biodivers; 2024 May; 21(5):e202400112. PubMed ID: 38606640
[TBL] [Abstract][Full Text] [Related]
12. VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents.
Ahmed EY; Abdel Latif NA; El-Mansy MF; Elserwy WS; Abdelhafez OM
Bioorg Med Chem; 2020 Mar; 28(5):115328. PubMed ID: 31992477
[TBL] [Abstract][Full Text] [Related]
13. Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides.
Eldehna WM; El Kerdawy AM; Al-Ansary GH; Al-Rashood ST; Ali MM; Mahmoud AE
Eur J Med Chem; 2019 Feb; 163():37-53. PubMed ID: 30503942
[TBL] [Abstract][Full Text] [Related]
14. Novel 5,6-disubstituted pyrrolo[2,3-d]pyrimidine derivatives as broad spectrum antiproliferative agents: Synthesis, cell based assays, kinase profile and molecular docking study.
Lee JH; El-Damasy AK; Seo SH; Gadhe CG; Pae AN; Jeong N; Hong SS; Keum G
Bioorg Med Chem; 2018 Nov; 26(21):5596-5611. PubMed ID: 30385226
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of some new 6-bromo-2-(pyridin-3-yl)-4-substituted quinazolines as multi tyrosine kinase inhibitors.
Farouk AKBAW; Abdelrasheed Allam H; Rashwan E; George RF; Abbas SE
Bioorg Chem; 2022 Nov; 128():106099. PubMed ID: 35994884
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, in silico ADMET, docking, and antiproliferative evaluations of [1,2,4]triazolo[4,3-c]quinazolines as classical DNA intercalators.
Alesawy MS; Ibrahim MK; Eissa IH; El-Adl K
Arch Pharm (Weinheim); 2022 Apr; 355(4):e2100412. PubMed ID: 35014084
[TBL] [Abstract][Full Text] [Related]
17. Novel 2-oxo-2-phenylethoxy and benzyloxy diaryl urea hybrids as VEGFR-2 inhibitors: Design, synthesis, and anticancer evaluation.
Ghannam IAY; El Kerdawy AM; Mounier MM; Abo-Elfadl MT; Ali IH
Arch Pharm (Weinheim); 2023 Feb; 356(2):e2200341. PubMed ID: 36398495
[TBL] [Abstract][Full Text] [Related]
18. New Carbothioamide and Carboxamide Derivatives of 3-Phenoxybenzoic Acid as Potent VEGFR-2 Inhibitors: Synthesis, Molecular Docking, and Cytotoxicity Assessment.
Heriz MH; Mahmood AAR; Tahtamouni LH; AlSakhen MF; Kanaan SI; Saleh KM; Yasin SR
Curr Cancer Drug Targets; 2024 May; ():. PubMed ID: 38747227
[TBL] [Abstract][Full Text] [Related]
19. Novel antiproliferative agents bearing substituted thieno[2,3-d]pyrimidine scaffold as dual VEGFR-2 and BRAF kinases inhibitors and apoptosis inducers; design, synthesis and molecular docking.
Hassan RA; Hamed MIA; Abdou AM; El-Dash Y
Bioorg Chem; 2022 Aug; 125():105861. PubMed ID: 35569190
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel piperazine-tethered phthalazines as selective CDK1 inhibitors endowed with in vitro anticancer activity toward the pancreatic cancer.
Akl L; Abd El-Hafeez AA; Ibrahim TM; Salem R; Marzouk HMM; El-Domany RA; Ghosh P; Eldehna WM; Abou-Seri SM
Eur J Med Chem; 2022 Dec; 243():114704. PubMed ID: 36095992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
